Thalidomide victims reject apology from German company that invented birth defect pregnancy drug

 

Alex Diaz
Saturday 01 September 2012 09:37 BST
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

A British charity has rebuffed the first apology for half a century from the German company which invented birth defect pregnancy drug Thalidomide.

The Grunenthal Group yesterday said in a statement it "regrets" the consequences of the drug, which was used to combat morning sickness but led to the birth of children without limbs during the 1950s and 1960s.

But the apology was rejected as insufficient by the Thalidomide Agency UK, which represents people who were affected by the drug in Britain.

Freddie Astbury, the charity's head consultant, said the company needed to "put their money where their mouth is" rather than simply express regret.

Mr Astbury, who was born in Chester in 1959 with no arms and no legs after his mother took the drug, said: "If they are serious about admitting they are at fault and regret what happened they need to start helping those of us who were affected financially."

Grunenthal chief executive Harald Stock yesterday said that the company had failed to reach out "from person to person" to the victims and their mothers over the past 50 years.

"Instead, we have been silent and we are very sorry for that," he added at an event in the western German city of Stolberg, where the company is based.

Thalidomide was pulled from the market in 1961 after it was linked to birth defects. Many victims have only recently received compensation.

Mr Astbury said the company had always denied it had anything to do with the birth defects and believes they are now apologising because of court proceedings brought by victims in Australia.

He said: "Being disabled is very expensive and Thalidomide people need help and care, and adaptations to their cars and homes.

"We just want people to live a comfortable life and that means Grunenthal have to pay for their mistake financially."

Thalidomide UK Agency says that there are 458 people currently in the UK who were affected by the drug, but that for every Thalidomide baby that lived there were 10 that died.

In January 2010, the Government expressed "sincere regret" for the decision to give the drug the stamp of approval and set up a funding scheme to help survivors cope.

Thalidomide was originally prescribed as a "wonder drug" for morning sickness, headaches, coughs, insomnia and colds.

Thalidomide babies often suffered missing or deformed limbs and extreme shortening of arms and legs, but the drug also caused malformations of the eyes and ears, genitals, heart, kidneys and digestive tract.

Thalidomide survivor Nick Dobrik dismissed the apology from the company.

"An apology should be an unreserved apology and not a conditional apology. It is strange when a company gives an apology which is not the truth, but is a lie," he told the BBC Radio 4 Today programme.

"We feel that a sincere and genuine apology is one which actually admits wrongdoing. The company has not done that and has really insulted the Thalidomiders."

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in